Skip to content

US · TEVA · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Teva Pharmaceutical Industries Limited (TEVA) intrinsic value and stock valuation

$39.23as of 2026-11-21 · Mkt cap 40.44B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Teva Pharmaceutical Industries Limited DCF and intrinsic value

InvestorsCraft values TEVA with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from TEVA’s statements →

Teva Pharmaceutical Industries Limited Graham Number

Graham Number: $13.79d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Tel Aviv, TA 6944020 tevapharm.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$17.3B+0.7% 5y CAGRd
20112025
Net income
$1.41B
20112025
Free cash flow
$1.15B+12.5% 5y CAGRd
20112025
Total equity
$7.91B-6.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$17.3B$16.5B$15.8B$14.9B$15.9B
Operating income$2.16B-$-303M$433M-$-2.2B$1.72B
Net income$1.41B-$-1.64B-$-559M-$-2.45B$417M
EPSd$1.2M-$-1.45M-$-499.55K-$-2.2M$376.7K
Operating cash flow$1.65B$1.25B$1.37B$1.59B$798M
Capital expenditure-$-501M-$-498M-$-526M-$-548M-$-562M
Free cash flow$1.15B$749M$842M$1.04B$236M
Total assets$40.7B$39.3B$43.5B$44B$47.7B
Total debt$17.4B$18.1B$20.2B$21.6B$23.5B
Net debt$13.8B$14.8B$16.9B$18.8B$21.3B
Total equity$7.91B$5.72B$8.13B$8.6B$11.2B
Cash and short-term investments$3.56B$3.3B$3.23B$2.8B$2.17B
Income statement
20252024202320222021
Revenue$17.3B$16.5B$15.8B$14.9B$15.9B
Cost of revenue$8.32B$8.48B$8.2B$7.95B$8.28B
Gross profit$8.94B$8.06B$7.65B$6.97B$7.59B
Research and development expenses$1.01B$1.06B$953M$838M$1.09B
Selling, general and administrative expenses$3.97B$3.7B$3.5B$3.45B$3.53B
Other expenses$1.79B$3.61B$2.76B$4.89B$1.26B
Operating expenses$6.78B$8.37B$7.21B$9.17B$5.88B
Cost and expenses$15.1B$16.8B$15.4B$17.1B$14.2B
Interest income$0.00$0.00$68M$0.00$0.00
Interest expense$916M$941M$1.03B$930M$891M
Depreciation and amortization$1B$1.06B$1.15B$1.31B$1.33B
Ebitda$3.14B$4.43B$1.56B-$-925M$4.41B
Operating income$2.16B-$-303M$433M-$-2.2B$1.72B
Total other income/expenses, net-$-919M-$-980M-$-1.06B-$-945M-$-1.05B
Income before tax$1.24B-$-1.28B-$-622M-$-3.14B$667M
Income tax expense-$-180M$676M-$-7M-$-643M$211M
Net income$1.41B-$-1.64B-$-559M-$-2.45B$417M
Weighted average shares outstanding$1.15B$1.13B$1.12B$1.11B$1.1B
Weighted average diluted shares outstanding$1.17B$1.13B$1.12B$1.11B$1.11B
Balance sheet
20252024202320222021
Cash and short-term investments$3.56B$3.3B$3.23B$2.8B$2.17B
Net receivables$3.71B$3.06B$3.41B$3.7B$4.53B
Inventory$3.18B$3.01B$4.02B$3.83B$3.82B
Total current assets$13.9B$12.6B$12.5B$12.1B$12.6B
Property, plant and equipment, net$4.42B$4.95B$6.15B$6.16B$6.48B
Goodwill and intangible assets$19.8B$19.6B$22.6B$23.9B$27.5B
Long-term investments$0.00$0.00$8M$0.00$0.00
Total non-current assets$26.8B$26.8B$31B$32B$35.1B
Total assets$40.7B$39.3B$43.5B$44B$47.7B
Accounts payable$2.53B$2.2B$2.6B$1.89B$1.69B
Short-term debt$1.82B$1.78B$1.67B$2.11B$1.43B
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$13.5B$12.8B$12.2B$11.5B$11B
Long-term debt$15.6B$16.3B$18.5B$19.5B$22B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$19.4B$20.8B$23.1B$23.9B$25.4B
Capital lease obligations$288M$296M$320M$349M$416M
Total liabilities$32.8B$33.6B$35.4B$35.4B$36.4B
Common stock$58M$58M$57M$57M$57M
Retained earnings-$-13.76B-$-15.17B-$-13.53B-$-12.98B-$-10.53B
Accumulated other comprehensive income (loss)-$-2.39B-$-3.15B-$-2.7B-$-2.84B-$-2.68B
Total equity$7.91B$5.72B$8.13B$8.6B$11.2B
Total investments$0.00$0.00$8M$0.00$0.00
Total debt$17.4B$18.1B$20.2B$21.6B$23.5B
Net debt$13.8B$14.8B$16.9B$18.8B$21.3B
Cash flow statement
20252024202320222021
Net income$1.42B-$-1.96B-$-615M-$-2.5B$456M
Depreciation and amortization$1B$1.06B$1.15B$1.31B$1.33B
Stock-based compensation$157M$123M$121M$124M$119M
Change in working capital-$-1.37B-$-435M-$-72M$1.36B-$-1.7B
Accounts receivable-$-173M$245M$12M$334M-$-574M
Inventory$152M$166M-$-147M-$-163M$380M
Accounts payable-$-15M$258M$1.59B$2.01B$764M
Net cash provided by operating activities$1.65B$1.25B$1.37B$1.59B$798M
Investments in property, plant and equipment-$-501M-$-498M-$-526M-$-548M-$-562M
Acquisitions, net$34M$28M$68M$61M$1.96B
Net cash used for investing activities$737M$792M$968M$656M$1.52B
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-2.15B-$-1.79B-$-1.91B-$-1.49B-$-2.17B
Net change in cash$256M$73M$393M$636M$21M
Cash at end of period$3.56B$3.3B$3.23B$2.83B$2.2B
Operating cash flow$1.65B$1.25B$1.37B$1.59B$798M
Capital expenditure-$-501M-$-498M-$-526M-$-548M-$-562M
Free cash flow$1.15B$749M$842M$1.04B$236M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Teva Pharmaceutical Industries Limited

        Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.

        CEO
        Richard D. Francis
        Employees
        37K
        Beta
        0.86

        Explore

        Frequently asked questions

        What is the intrinsic value of Teva Pharmaceutical Industries Limited (TEVA)?

        Teva Pharmaceutical Industries Limited (TEVA) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TEVA undervalued?

        TEVA trades at a price of $39.23 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.